• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a nucleic acid molecule encoding a fusion protein, the nucleic acid molecule comprising in the 5'-3 'sense of transcription at least one nucleic acid sequence encoding a dna binding domain., and a nucleic acid sequence encoding a catalytic domain of the fokl type, wherein at its 3 'end it comprises a nucleic acid sequence encoding a peptide comprising between 18 and 23 amino acids, with a fusion protein obtainable for example from the transcription of said molecule, and with a method to modify the genetic material of a cell through the use of said molecule or protein. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2594486A1
    申请号:ES201530874
    申请日:2015-06-19
    公开日:2016-12-20
    发明作者:Eusebio GAINZA LAFUENTE；Garazi GAINZA LUCEA；Angel DEL POZO PEREZ；Marta PASTOR NAVARRO；José Luis Pedraz Muñoz；Miguel VIÑAS CIORDIA；Daniel BACHILLER PEREZ；Victor GALVEZ JEREZ
    申请人:BIOPRAXIS RES AIE；BIOPRAXIS RESEARCH AIE；Euskal Herriko Unibertsitatea；Consejo Superior de Investigaciones Cientificas CSIC；Universitat Autonoma de Barcelona UAB；Universitat de Barcelona UB；Fundacio d'Investigacio Sanitaria de les Illes Balears；
    IPC主号:
    专利说明:

    Nucleic acid molecule, fusion protein and method to modify the genetic material of a cell
    SECTOR OF THE TECHNIQUE
    The present invention relates to molecular tools that allow modifying the genetic material of a cell.
    PREVIOUS STATE OF THE TECHNIQUE
    In recent years, new types of molecular tools have appeared that allow the genetic material of the cells to be modified. As an example, tools such as “Zinc Finger” nucleases, CRISPR / Cas9 or TALENs have led to a technological revolution in this field since all of them are capable of cutting the double helix of DNA into specific genome sequences, which opens the real possibility of modifying the genetic information of living cells at will. These tools, also known as sequence specific nucleases, are characterized by having a DNA binding domain and another catalytic domain that cut into a sequence adjacent to the sequence recognized by the binding domain.
    There have been numerous efforts to improve the effectiveness and specificity of such tools in targeted genomic editing techniques. By way of example, EP2510096 A1 describes a TALEN that improves cutting selectivity and WO2012015938 A2 describes new variants of FokI-like domains with at least one mutation in some of the amino acid residues with respect to the wild type.
    Modifying a peptide sequence by adding a sequence that encodes between 18 and 23 amino acids creates a different protein that can be inert or have functional characteristics other than the starting proteins. In fact, cases have been described in which the addition of 2A peptides at the C'terminal end of a protein has caused its inactivation. As an example, some of the structures described in Anal Biochem, 2005.343 (1): p.116-24 “FDMV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein”.
    EXHIBITION OF THE INVENTION
    The object of the invention is to provide a nucleic acid molecule, a fusion protein and a method for modifying the genetic material of a cell, as defined in the claims.
    One aspect of the invention relates to a nucleic acid molecule encoding a fusion protein, the nucleic acid molecule comprising 5'--- 3 'transcription meaning at least:
    (to) a nucleic acid sequence encoding a DNA binding domain, and
    (b) a nucleic acid sequence encoding a catalytic domain of the FokI type, where at its 3'-end it comprises a nucleic acid sequence encoding a peptide comprising between 18 and 23 amino acids.
    Another aspect of the invention relates to a fusion protein that comprises in the N-terminal to C-terminal sense at least one DNA binding domain and at least one FokI type catalytic domain, wherein said FokI type catalytic domain has attached to its C-terminal end a peptide comprising between 18 and 23 amino acids.
    Another aspect of the invention relates to a method for modifying the genetic material of a cell, which comprises the steps of:
    (i) provide a cell that contains a DNA target nucleotide sequence, and
    (ii) introducing into said cell at least said nucleic acid molecule, or at least one nucleic acid molecule encoding at least said fusion protein, and inducing the expression of said at least one nucleic acid molecule, or
    (iii) introducing into said cell at least one said fusion protein such that the binding domain recognizes the target nucleotide sequence and the catalytic domain of the FokI type can cut into a nucleotide sequence adjacent to the target nucleotide sequence.
    The presence of a new element at the C-terminal end of the FokI domain represents an approximately 20% increase in the size of that domain. Studies by the inventors have shown that this modification improves the cutting efficiency of FokI.
    The nucleic acid molecule or fusion protein of the invention may be useful in the treatment of inherited diseases, in particular monogenic inherited diseases. Therefore, another aspect of the invention is directed to the nucleic acid molecule or the protein defined above or the modified cell according to the method defined above, for use as a medicament or a therapeutic composition.
    Another aspect of the invention is directed to a method of treatment and / or prevention of a disease, preferably in the immune system, preferably caused by HIV and / or related species, or a hereditary monogenic disease and comprising administering a therapeutically amount effective of the nucleic acid molecule or fusion protein defined above or of the modified cell according to the method defined above, together with pharmaceutically acceptable carriers or excipients, in a subject in need of such treatment and / or prevention, including a human.
    These and other advantages and features of the invention will become apparent in view of the figures and the detailed description of the invention.
    DESCRIPTION OF THE DRAWINGS
    Figure 1 shows a diagram of a bicistronic gene comprising a ribonucleic acid molecule according to an embodiment of the invention.
    Figure 2 shows a diagram of a tricistronic gene comprising a ribonucleic acid molecule according to an embodiment of the invention.
    Figure 3 shows the structure of the proteins produced from the bicistronic gene of Figure 1.
    Figure 4 shows the mechanism of action of proteins produced from the bicistronic gene of Figure 1.
    Figure 5 shows the results of example 2 of the activity of a fusion protein of the invention with respect to the activity of a prior art protein.
    5 Figure 6 shows a scatter diagram of cells transfected with two fusion proteins according to an embodiment of example 3.
    Figure 7 shows the activity of fusion and fluorescence selection proteins according to an embodiment of example 3.
    Figure 8 shows the production of T lymphocytes with two null copies of the CCR5 gene according to an embodiment of example 4..
    DETAILED EXHIBITION OF THE INVENTION
    A first aspect of the invention relates to the nucleic acid molecule that encodes
    15 a fusion protein that the inventors have developed and comprises in the 5'--- 3 'sense of transcription at least one nucleic acid sequence encoding a DNA binding domain and a nucleic acid sequence encoding a catalytic domain of the type FokI, wherein at the 3'-end of said nucleic acid sequence encoding the catalytic domain of type FokI comprises a nucleic acid sequence encoding a peptide
    20 comprising between 18 and 23 amino acids, preferably 21 amino acids.
    The terms nucleic acid, polynucleotide, oligonucleotide or nucleotide are interchangeable and refer to deoxyribonucleic acids or ribonucleic acids, in a linear conformation.
    or circular, either single-chain or double-stranded. These terms may cover
    25 known analogs of natural nucleotides, as well as nucleotides that are modified in the base, sugar and / or phosphate moieties. In general, an analog of a particular nucleotide has the same specific base pairing as said particular nucleotide.
    In the context of the present invention, "fusion protein" means a protein comprising at least one polypeptide comprising a DNA binding or recognition domain and a FokI type catalytic domain that cuts said DNA.
    In the context of the invention, the catalytic domain of the FokI type is understood as the catalytic domain of an FokI enzyme. The FokI enzyme is a restriction endonuclease of the IIS type of bacteria found naturally in Flavobacterium okeanokoites. In the context of the invention the catalytic domain may be in its wild homodimer conformation or in bound heterodimer conformation.
    In a particular embodiment, the peptide comprising between 18 and 23 amino acids is a peptide of type 2A.
    In the context of the invention, the type 2A peptide refers to a peptide sequence of between 18 and 23 amino acids located between two functional polypeptides or proteins.
    2A peptides are originally found in different viruses of the Picornavirus family, where they act in the protein synthesis process. All proteins encoded by the genome of these viruses are comprised in a single polycistron or single reading frame. Elements 2A induce the interruption of the process of synthesizing the polyprotein chain by means of the process called ¨ribosomal skipping¨, whereby the different proteins encoded in the genome of the virus end up being produced independently.
    In a particular embodiment said type 2A peptide comprises 21 amino acids. Preferably, the peptide of type 2A is of type T2A.
    In a particular embodiment, said type 2A peptide comprises the amino acid sequence SEQ ID NO: 1.
    By "DNA binding domain" is meant a domain comprised within a polypeptide, which comprises at least one structure that recognizes the DNA to which it binds. A DNA binding domain can recognize a specific DNA sequence (a recognition sequence) or it can have a general affinity for DNA. Examples of polypeptides comprising the DNA binding domain are: ZFN, CRISPR / Cas9 or TALE.
    In a particular embodiment the binding domain of the nucleic acid molecule according to the above characteristics is of the TALE type.
    By TALE is meant a TAL effector or TALE polypeptide or TALE protein comprising a DNA binding domain that has a plurality of DNA binding repeats, where each repeat comprises an RVD that determines the recognition of a
    5 base of the target DNA.
    In a particular embodiment, the nucleic acid molecule according to the above characteristics comprises in the 5'--- 3 'sense of transcription:
    10 (a) the nucleic acid sequence encoding the DNA binding domain comprising a first segment of between 150 and 600 base pairs, preferably between 470 and 550 base pairs, encoding the N-terminal end of a protein TALE and a nuclear localization signal, a second segment of between 1100 and 2900 base pairs that encode the binding domain of the TALE type to DNA, and a
    15 third segment of between 40 and 850 base pairs that encode the Cterminal end of the TALE protein, and
    (b) the nucleic acid sequence encoding the catalytic domain of the FokI type comprising a first segment of between 550 and 600 base pairs, preferably between 590 and 600 base pairs, encoding the domain
    FokI type catalyst followed by a segment of between 50 and 70 base pairs, preferably 69 base pairs, encoding the peptide comprising between 18 and 23 amino acids, preferably 21 amino acids.
    In the context of the invention, by nuclear localization signal (hereinafter NLS)
    25 is understood as an amino acid sequence that marks a protein so that it can be imported into the cell nucleus through the transport proteins known as import receptors.
    In a particular embodiment, the nucleic acid molecule according to the characteristics
    30 above, in the 5'--- 3 'sense of transcription following the nucleic acid sequence encoding the peptide comprising between 18 and 23 amino acids, comprises a nucleic acid sequence encoding a transcription identifying protein

    In a preferred embodiment, following the nucleic acid sequence encoding the catalytic domain of the FokI type comprises a nucleic acid sequence encoding the transcription identifier protein comprising between 700 and 1000 base pairs.
    In the context of the invention, a transcription identifier protein is understood as a marker which, due to its transcription, allows identifying and selecting those cells in which the fusion protein of the invention has been expressed. As markers are included without limitation, products that confer resistance to antibiotics, products that confer an advantage of selective growth when the nucleic acid molecule is expressed in the presence of a substrate and / or fluorescent proteins.
    In a preferred embodiment, the transcription identifying protein is a fluorescent protein. Examples of fluorescent proteins include, without limitation, GFP, tdTomato, IRFP, mEmerald, DsRed, EBFP, EYFP, Cerulean, ECFP, etc. In a preferred embodiment the fluorescent protein is an mCherry protein or an EGFP protein.
    The nucleic acid molecule according to the above characteristics can form a monocistronic gene or a polycistronic gene, preferably a bicistronic gene or a tricistronic gene.
    One of the advantages that the nucleic acid molecule is forming a polycistronic gene is that the fusion protein and the transcription identifier protein are expressed from the same promoter. The identification and selection by fluorescence for example, allows to obtain a cell population enriched in cells that have gone through a process of genetic modification. The structure of the nucleic acid molecule of the invention minimizes the risk of the selection of false positives that is inherent in the placement of the sequence encoding the fluorescent protein in situation 5 'with respect to the catalytic domain of FokI.
    In a particular embodiment, the nucleic acid molecule constitutes a bicistronic gene that in the 5'--- 3 'sense of transcription encodes at least one fusion protein according to the above characteristics and a transcription identifying protein, preferably, a fluorescent protein .
    In another particular embodiment, the nucleic acid molecule constitutes a tricistronic gene that in the 5'--- 3 'sense of transcription encodes at least a first TALE protein, a FokI catalytic domain where at its C-terminal end it comprises a peptide that it comprises between 18 and 23 amino acids, preferably of the type 2A, a second TALE protein, a catalytic domain of the FokI type where at its C-terminal end it comprises a second peptide comprising between 18 and 23 amino acids, preferably of the type 2A, more preferably of the T2A type, and a transcription identifying protein, preferably a fluorescent protein.
    An example of a bicistronic gene 10 comprising an embodiment of the nucleic acid molecule of the invention expressing a fusion protein 100 and a fluorescent protein 50 is presented in Figure 1, said bicistronic gene comprising 5'--- 3 ´ of transcription:
    - a sequence 1 encoding a promoter
    - the nucleic acid sequence 2 encoding the DNA binding domain comprising a first segment encoding the N-terminal end 20 of a TALE protein and a nuclear localization signal, a second segment encoding the binding domain of the TALE type 21 to DNA, and a third segment 22 that encodes the C-terminal end of the TALE protein, and
    - the nucleic acid sequence encoding the catalytic domain of the FokI type comprising a first segment 3 that encodes the catalytic domain of the FokI type 30 followed by a segment 4 encoding the peptide 40 comprising between 18 and 23 amino acids, preferably 23 amino acids, and
    - the nucleic acid sequence 5 encoding the fluorescent protein 50.
    An example of the structure of the proteins produced from the bicistronic gene of Figure 1 is presented in Figure 3.
    An example of a tricistronic gene comprising an embodiment of the nucleic acid molecule of the invention is presented in Figure 2, wherein from the same promoter 1 a first fusion protein according to the invention is expressed 20,21,22 , 30,40, a second fusion protein 20,21,22,30,40 according to the invention and a fluorescent protein 50.
    An advantage of this arrangement of these polycistronic genes is that both the fusion protein and the fluorescent protein are expressed from the same promoter. This configuration minimizes the risk of the selection of false positives that is inherent in the placement of the sequence encoding the fluorescent protein in a situation 5 'in relation to the catalytic domain of FokI.
    When the nucleic acid molecule that forms the monocistronic or polycistronic gene is a ribonucleic acid, said molecule comprises at the 5 'end a structure called CAP known to one skilled in the art. In general, this structure provides stability to the ribonucleic acid messenger that could be transcribed from the gene.
    When the nucleic acid molecule that forms the monocistronic or polycistronic gene is one of deoxyribonucleic acid, the nucleotide sequences of the gene are adapted to the codon use of the plant, animal or human organism, in which they are used.
    Another aspect of the invention relates to a fusion protein that comprises in the N-terminal to C-terminal sense at least one DNA binding domain and at least one FokI type catalytic domain, wherein said FokI type catalytic domain has attached to its C-terminal end a peptide comprising between 18 and 23 amino acids, preferably 21 amino acids.
    In a particular embodiment, the DNA binding domain is of the TALE type.
    In a particular embodiment, the peptide comprising between 18 and 23 amino acids is a 2A peptide, preferably of the T2A type.
    In a preferred embodiment, the T2A peptide comprises an amino acid sequence SEQ ID NO: 1.
    In a particular embodiment, the fusion protein comprises N-terminal to Cterminal at least:
    - a first segment between 50 and 200 amino acids in length corresponding to the N-terminal end of a TALE protein,
    - a TALE type binding domain that provides specific binding to a target nucleotide sequence,
    - a segment between 20 and 100 amino acids in length corresponding to the C-terminal end of a TALE protein, and
    - a catalytic domain of the FokI type where at its C-terminal end it comprises a peptide of between 18 and 23 amino acids, preferably of 21 amino acids.
    Said modified FokI type catalytic domain may be in its wild homodimer conformation or in its bound heterodimer conformation.
    Another aspect of the invention relates to a method for modifying the genetic material of a cell, which comprises the steps of:
    5 (i) provide a cell containing a DNA target nucleotide sequence, and
    (ii) introducing into said cell at least one nucleic acid molecule according to any of the above characteristics, or at least one nucleic acid molecule encoding at least one fusion protein according to any of the
    10 above characteristics, and induce the expression of said at least one nucleic acid molecule, or
    (iii) introducing into said cell at least one fusion protein according to any of the above characteristics,
    such that the binding domain recognizes the target nucleotide sequence and the catalytic domain of the FokI type can cut into a nucleotide sequence adjacent to the target nucleotide sequence.
    In the context of the invention, the cell can be plant or human or animal mammal.
    In one embodiment the cell is of a vegetable.
    In another embodiment the cell is from an animal mammal.
    In another embodiment, the cell is from a human mammal. Examples of a human cell without limitation are the lymphocyte, the hematopoietic stem cell, the fibroblast of a biopsy or an induced pluripotent stem cell.
    The target nucleotide sequence can be in any cell type, tissue or eukaryotic organism.
    In the context of the invention adjacent is understood within the target sequence or at a distance of between 5 and 20 base pairs in the 5'---- 3 'direction of the target sequence.
    In a particular embodiment, at least two nucleic acid molecules are introduced into the cell, each molecule expressing a fusion protein of the invention. At least these two fusion proteins are complementary.
    In another particular embodiment, at least two fusion proteins 5 according to the invention are introduced into the cell. These at least two fusion proteins are complementary.
    In the context of the invention, complementary means that at least each of the proteins recognizes a target sequence in a certain region of the cell genome, separated by between 5 and 20 base pairs from that recognized by the other protein. The mechanism of action of the two complementary fusion proteins is known by the
    10 expert in the field as shown in figure 4:
    - the binding domain 21 of a first fusion protein recognizes a first target nucleotide sequence to which it binds and the binding domain 21 of a second fusion protein recognizes a second target nucleotide sequence to which it binds,
    15 -the FokI 30 catalytic domains of each fusion protein form a dimer between them, and
    - the dimer cuts into a nucleotide sequence between the target nucleotide sequences recognized by the binding domain of each fusion protein.
    In the context of the invention the FokI catalytic domain may be in its wild homodimer conformation or in bound heterodimer conformation.
    In a preferred embodiment, the nucleic acid molecule or nucleic acid molecules that are introduced into the cell comprises at least 5'--- 3 'transcription sense:
    - a nucleic acid sequence encoding a DNA binding domain of type 25 TALE, and
    - a nucleic acid sequence encoding a catalytic domain of the FokI type, where at its 3'-end comprises a nucleic acid sequence encoding a peptide of type 2A, preferably of the type T2A, comprising an amino acid sequence SEQ ID NO: one.

    Additionally, the nucleic acid molecule of this preferred embodiment, in the 5'-3 'direction following the type 2A peptide, comprises a nucleic acid sequence encoding a transcription identifier protein, preferably a fluorescent protein. This fact brings additional advantages to the method since it allows the identification and selection of said cell.
    In this preferred embodiment, the nucleic acid molecule, preferably nucleic acid, may be forming a polycistronic gene, preferably a bicistronic gene or a tricistronic gene as described above.
    In a particular embodiment, at least two nucleic acid molecules, preferably, two bicistronic genes, are introduced into the cell. In this embodiment, preferably, each bicistronic gene expresses a fusion protein 100 and a fluorescent protein 50 with a different and / or differentiable emission spectrum between both fluorescent proteins. This feature has an additional advantage, since it allows to identify and select by fluorescence the cells in which one, both or none of the fusion proteins encoded by the bicistronic genes are transcribed. The fusion proteins obtained from the transcription of these two bicistronic genes are complementary. The identification and selection by fluorescence allows enriching a genetically modified cell population according to the method of the invention.
    In a particular embodiment, the modified cells according to the method of the invention are identified and selected based on the fluorescence emitted by said cells. In another embodiment, these selected modified cells are amplified in culture and at least two nucleic acid molecules described above are reintroduced. The modified cells in this second phase are identified and selected based on the fluorescence emitted by said cells. When the nucleic acid molecule introduced into the cell is the tricistronic gene described above, only a single fluorescence will be obtained. In another particular embodiment at least one tricistronic gene is introduced into the cell. In this embodiment, the tricistronic gene expresses two complementary fusion proteins between them and a fluorescent protein. This embodiment allows to identify by fluorescence those cells in which the two fusion proteins have been transcribed or expressed.
    In any of the foregoing cases, at least one tricistronic gene encoding two fusion proteins according to the invention may be introduced in addition to each other and a single fluorescent protein.
    The introduction of the nucleic acid molecule or molecules of the invention can be carried out by
    5 the different mechanisms known to the person skilled in the art. The nucleic acid molecule of the invention can be introduced into the cell by a viral or non-viral administration system. Non-limiting examples of viral delivery systems include DNA viruses, RNA viruses, retroviral vectors, lentiviral vectors, adenoviruses, pox viruses, herpes viruses and / or adeno-associated viruses. Non-limiting examples of
    Non-viral administration comprises nucleofection, electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, niosomes, nucleic acid conjugates with polycations or lipids, naked DNA or associated with a nanoparticle. , the artificial virions, the inducing agents of the taking of DNA by the cell and the sonoporation.
    In a particular embodiment, the nucleic acid molecule is introduced in the form of a plasmid by nucleofection.
    In another particular embodiment, the nucleic acid molecule is administered by a lentiviral vector.
    In another particular embodiment, the nucleic acid molecule is administered by an adenovirus. Non-limiting examples of other viruses are adeno-associated viruses.
    In one embodiment, the nucleic acid molecule or molecules expressing the fusion protein of the invention are administered directly to the organism or patient (in vivo).
    In another embodiment, the nucleic acid molecule or molecules expressing the fusion protein of the invention are administered to cells in culture (in vitro) and once the cell is modified
    25 introduced into an organism or the patient (ex vivo).
    In one embodiment, the cells in culture are cells obtained from the patient to be treated or from the organism to be genetically modified according to the method of the invention.
    The nucleic acid molecules or fusion proteins of the invention are advantageously used:
    - to replace a genomic sequence with a non-identical homologous sequence (i.e. homologous recombination),
    - to erase a genomic sequence by cutting DNA at one or more sites in the genome, followed by the elimination of the sequence between the cut-off points and the junction thereof,
    - to introduce an exogenous sequence at a specific point of the genome where it was not previously found, - for the detection of cellular factors that facilitate homologous recombination; and / or - to replace a wild type sequence with a mutant sequence, or to convert an allele to a different allele.
    The modification of the genetic material is therefore applicable for the directed genetic modification of a cell (deletion or insertion), for genomic editing in its different forms, for the generation of genetically modified animals or plants, and for gene therapy.
    Any pathology or disease in plants, animals and humans dependent or mediated by a particular genomic sequence, in any way, can be treated, corrected or relieved using the methods and compositions described herein.
    By way of example, the target nucleotide sequence is in a gene related to the treatment of acquired immunodeficiencies, cancer immunotherapy, lysosomal deposition diseases (eg, Gaucher disease, GM1, Fabry disease and disease of Tay-Sachs), mucopolysaccharidosis (for example, Hunter's disease, Hurler's disease), and hemoglobinopathies (for example, sickle cell diseases, HbC, thalassemia, and hemophilia).
    The methods and compositions described herein also allow the treatment of infections (viral or bacterial) in a host, for example, by blocking or inactivating the expression of viral or bacterial receptors, thus preventing infection and / or diffusion in a host organism In a particular embodiment, the target nucleotide sequence is in the human CCR5 gene.
    The human CCR5 gene encodes the main correceptor used by the human immunodeficiency virus (HIV), which causes AIDS, to penetrate T lymphocytes. It has been proven that the removal of the CCR5 correceptor prevents entry of the virus into T lymphocytes. and, therefore, the progress of the infection and the development of the disease. In a particular embodiment, the molecule of the invention or the fusion proteins of the invention result in the genetic modification of the CCR5 gene resulting in inactivation of the CCR5 correceptor in primary lymphocytes of AIDS patients. Genetic modification occurs in the DNA segment between the target nucleotide sequences of the human CCR5 gene recognized by the binding domains of at least two complementary fusion proteins, the target nucleotide sequences being preferably SEQ ID NO: 2 and SEQ ID NO: 3.
    In a particular embodiment, in a first phase of inactivation at least two nucleic acid molecules, preferably two complementary bicistronic genes of the invention, are introduced into T lymphocytes, for example according to Figure 1, specific for the CCR5 gene. Transcription of the genes produces two complementary TALEN fusion proteins and two fluorescent proteins, preferably mCherry and EGFP. TALEN proteins will recognize their respective target sequences, preferably SEQ ID NO: 2 and SEQ ID NO: 3, located at a distance that allows the two FokI catalytic domains to dimerize and cut the double strand of DNA. At the same time, the red and green fluorescence emitted by the respective fluorescent proteins allow to identify those cells in which the two bicistronic genes have been transcribed. The double fluorescence allows them to be isolated by means of a cell separator and thus obtain a population of cells in which practically 100% present at least one of the two inactivated CCR5 alleles. The T lymphocytes thus obtained can undergo a second phase of inactivation. To do this, once isolated and amplified in culture, at least two complementary bicistronic genes of the invention are introduced again, as described above, modifying the copy of the CCR5 gene that has not yet been modified. Both T lymphocytes produced in the first phase, which will be mostly heterozygous for the mutation of the CCR5 gene, and those produced in the second phase, which will be mostly homozygous for the mutation of the CCR5 gene, are administered for therapeutic purposes at original donor The T lymphocytes produced are partially or totally resistant to HIV infection, depending on whether they are homozygous or heterozygous for the mutation of the CCR5 gene. The protection offered by modified T lymphocytes will have a limited duration, so to extend it over time, periodic administrations of modified T lymphocytes are performed.
    In order to achieve permanent protection against HIV, hematopoietic stem cells are transplanted to the patient who have previously had the CCR5 gene modified by using the molecule of the invention or the fusion protein of the invention or the method of the invention. . The inactivation procedure will be the same as described for T lymphocytes. Hematopoietic stem cells are previously obtained from the patient, or they may have been produced in vitro from iPS cells derived from differentiated cells of the patient. The modification of the CCR5 gene can also be performed in the iPS cell itself according to the process described above. In any of the above cases, the procedure for modifying the CCR5 gene may also be performed by using a single tricistronic gene that encodes two fusion proteins according to the invention, complementary specific to the CCR5 gene and a single fluorescent protein.
    In another particular embodiment, the target nucleotide sequence is in a gene related to a genetic disease, preferably monogenic.
    By way of non-limiting example, genetic diseases include, but are not limited to, prolidase deficiency, siliadosis, galactosiliadosis, α mannosidosis, β mannosidosis, aspartylglucosaminuria, fucosidosis, Schindler's disease, metachromatic leukodystrophy, multiple sulfatase deficiency, leukodystrophy Floboids, Pompe disease, Farber lipogranulomatosis, Wolman disease and cholesteryl ester storage disease, pycnodistostosis, ceroidolipofuscinosis, cystinosis, Salla disease, mucolipidosis III or IV, Danon disease, zeroidolipofuscinosis 6 and 8, the disease Chediak Higashi, Griscelli diseases type 1, 2 and 3, Hermansky Pudliak 2 disease, X-linked retinoschisis, stargardt disease, choroideremia, retinitis pigmentosa 1-57, achondroplasia, achromatopsia, acid maltose deficiency, deficiency of adenosine deaminase (OMIM No. 102700), adrenoleukodystrophy, Aicardi syndrome, alpha-1 antitrypsin, alpha-thalassemia, androgen insensitivity syndrome, Apert syndrome, right ventricular arrhythmogenesis, dysplasia, telangictasia ataxia, Barth syndrome, beta-thalassemia, Bean syndrome, Canavan disease, chronic granulomatous diseases ( CGD), Cri du Chat syndrome, cystic fibrosis, Dercum disease, ectodermal dysplasia, Fanconi anemia, progressive ossifying fibrodysplasia, fragile X syndrome, galactosemia, Gaucher disease, generalized gangliosidosis (eg, GM1), hemochromatosis, hemoglobin C mutation in the 6.sup.th codon of beta-globin (HBC), hemophilia, Huntington's disease, Hurler's syndrome, hypophosphatasia, Klinefleter syndrome, Krabbes disease, Langer-Giedion syndrome, deficiency of leukocyte adhesion (LAD, OMIM No. 116920), leukodystrophy, long QT syndrome, Marfan syndrome, Moebius syndrome, mucopolysaccharidosis (MPS), rh syndrome nail tula, nephrogenic diabetes insipidus, neurofibromatosis, Neimann-Pick disease, osteogenesis imperfecta, porphyria, Prader-Willi syndrome, progeria, Proteus syndrome, retinoblastoma, Rett syndrome, Rubinstein-Taybi syndrome, Sanfilippo syndrome, severe combined immunodeficiency (SCID), Shwachman syndrome, sickle cell disease (sickle cell anemia), Smith-Magenis syndrome, Stickler syndrome, Tay-Sachs disease, Absent thrombocytopenia Radio ( ART), Down syndrome, Treacher Collins syndrome, trisomy, tuberous sclerosis, Down syndrome, Tumer lymphoproliferative syndrome, urea cycle disorder, von Hippel-Lindau disease, Waardenburg syndrome, Williams syndrome, Wilson's disease, and X-linked Wiskott-Aldrich syndrome (XLP, OMIM No. 308240).
    Therefore, another aspect of the invention is directed to the use of the nucleic acid molecule or the fusion protein or the modified cell according to the method of the invention for use as a medicament or for use in the treatment of the aforementioned diseases .
    Another aspect of the invention relates to the use of the nucleic acid molecule of the invention or the fusion protein of the invention or the genetically modified cell according to the method of the invention, to prepare a medicament or a therapeutic composition for the treatment or Disease prevention In a particular embodiment, said medicament or said therapeutic composition is used for the treatment or prevention of AIDS.
    In another particular embodiment, said medicament or said therapeutic composition is used for the treatment or prevention of hereditary diseases, preferably monogenic hereditary diseases.
    Another aspect of the invention is directed to a method of treatment or prevention of one of the diseases mentioned above, which comprises administering a therapeutically effective amount of the nucleic acid molecules or fusion protein defined above, or of the modified cell genetically according to the method of the invention, together with pharmaceutically acceptable excipients or carriers, in a subject in need of such treatment and / or prevention, including a human.
    The term "prevention or treatment" in the context of the invention means the administration of nucleic acid molecules or fusion proteins according to the invention to preserve health in a patient who suffers or is at risk of suffering from one of the above diseases. described. Such terms also include the administration of nucleic acid molecules or fusion proteins according to the invention to prevent, improve, alleviate or eliminate one or more symptoms associated with the disease. The term "improve" in the context of this invention is understood to mean any improvement in the situation of the treated patient, either subjective (sensation of or in the patient) or objectively (measured parameters).
    The nucleic acid molecules or the modified proteins or cells of the present invention may be part of a therapeutic composition. Such therapeutic compositions include any solid, semi-solid or liquid composition.
    The therapeutic composition of the invention comprises the nucleic acid molecule or the fusion protein or the modified cell according to the invention together with vectors, excipients.
    or pharmaceutically acceptable carriers, in a subject in need of such treatment and / or prevention, including a human. The person skilled in the art can determine which additional components can be used and if necessary, many of them being commonly used in therapeutic compositions.
    The term "therapeutically effective amount" in the context of this invention refers to the amount of composition that, once administered, is sufficient to prevent or treat one or more symptoms derived from the disease. The particular dose administered according to the present invention will be determined according to the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated and similar considerations.
    The term "pharmaceutically acceptable excipients or carriers" refers to pharmaceutically acceptable materials, composition or vehicles. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for use in contact with human and animal tissues or organs without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications consistent with a reasonable benefit / risk ratio.
    In the following, some illustrative examples are described that highlight the features and advantages of the invention. However, they should not be construed as limiting the object of the invention as defined in the claims.
    Examples
    Example 1: Preparation of a bicistronic nucleic acid molecule according to the invention
    The new bicistronic genes have been constructed with the fluorescence protein bound by a 2A element to the C-terminal end of the FokI monomer. The union was made by successive extensions, by PCR, of the fragments to be assembled. In a first series of reactions two fragments were amplified. The first consisted of the 3 'part of the coding region for the catalytic domain of FokI and fragment 2A. The second had a 5 'overlapping zone with the 3' end of the first, followed by the coding sequence for the corresponding fluorescent protein. In the second amplification reaction the two products of the first series were mixed, with the primers corresponding to the 5 'end of the first reaction and the 3' end of the second. The PCR reaction performed with this mixture gave rise to a DNA fragment that could be linked by classical methods of molecular genetics to the classical structure of a TALEN, replacing the 3 'fragment of the FokI domain described in the prior art, by another containing the addition of 21 amino acids and the corresponding fluorescent protein.
    Example 2: Cutting efficiency of a fusion protein according to the invention.
    The cutting efficiencies of two complementary pairs of fusion proteins 100 obtained according to example 1 were compared with respect to a complementary pair of a TALEN 80 of the prior art. The proteins produced according to Example 1 have the 21 amino acid fragment with the sequence SEQ ID NO: 1 added to the C-terminal end of the FokI catalytic domain. The 80 proteins lack those 21 amino acids. The two complementary protein pairs are specific respectively for regions near Δ32 in the CCR5 gene and ΔF508 in the CFTR gene, both human, in two cell types: K562 and primary T lymphocytes (T-cells). The genes coding for both proteins were introduced plasmidically into the cells by Nucleofection (LONZA). The Surveyor® method known to the person skilled in the art was used to measure the cutting efficiency. The results were quantified by virtual electrophoresis and densitometry performed with a Bioanalyzer 2100 molecular analyzer from Agilent Technologies. The same amount of cells and the same amount of proteins 100 and 80 were used for each experiment. Both proteins recognize the same target sequences within each gene. With the Surveyor method, cutting efficiency is measured by the relative abundance of digestion products compared to the uncut target sequence (346 bp for CCR5 and 360 bp for CFTR). The efficiency results obtained are presented in Figure 5. The values obtained (as percentages of the unmodified allele) are indicated below each column. The arrows indicate the position and size of the unmodified alleles (bands corresponding to 346 bp and 360 bp) and the corresponding digestion products (200 bp, 146 bp, 210 bp and 150 bp). PM: molecular weight marker. Surveyor® positive control: internal control of kit operation. The numerical scale on the left is formed by arbitrary values of displacement used by the device where the measurement was made (Bioanalyzer).
    From the results obtained it is concluded that the fusion proteins of the invention are more effective than the prior art proteins.
    Example 3: Identification and enrichment of a cell population subjected to the method of genetic modification according to the invention.
    The results of two experimental series performed with K562 cells are presented. In each one a different target gene has been inactivated. In one case, the target gene has been CCR5 and in another CFTR. In each experiment the corresponding cells have been transfected with a pair of bicistronic genes (hereafter referred to as TALEN-F1 and TALEN-F2), each bicistronic gene encoding a fusion protein 100 and a fluorescent protein 50. The fusion proteins obtained of the transcription of the two types of bicistronic gene are complementary (specific respectively for regions near Δ32 in the CCR5 gene and ΔF508 in the CFTR gene), while fluorescent proteins obtained with each type of gene have a different emission spectrum and / or differentiable between both fluorescent proteins. One of the genes encodes an mCherry fluorescent protein and the other gene the EGFP protein. The identification and selection by fluorescence allows enriching a genetically modified cell population according to the method of the invention and this has been demonstrated by the results obtained. In Figure 6, the dot plots represent the distribution of the cells according to the intensity of the expression of the two fluorescent proteins obtained by the cell separator. In abscissa the emission corresponding to GFP is represented and in ordinates the one corresponding to mCherry. The parameters of the cell separator have been adjusted so that cells that only express one of the two fluorescent proteins are grouped together with the double negatives in the lower left quadrant. The upper right quadrant contains the cells that express the two fluorescent proteins with greater intensity. The percentages correspond to the percentage of cells that express the two fluorescent proteins against the total cells of each experiment.
    In a second phase, the nuclease or shear activity of the fusion proteins of the invention was determined by the Surveyor® method cited above. To do this, the DNAs of isolated cells expressing the two fluorescent proteins were extracted. Figure 7 reflects the results obtained with the human genes CCR5 and CFTR in K562 cells. In each case the same amount of cells and bicistronic genes was used and the cut percentages of the fusion proteins were compared in three situations:
    - Transfection with TALEN-F1 and TALEN-F2 and without fluorescence selection (column 100). -First transfection with TALEN-F1 and TALEN-F2 and fluorescence selection (cut column 1). -Second transfection with TALEN-F1 and TALEN-F2 and fluorescence selection (cut column 2).
    After the first transfection and selection cycle (cut1) it can be seen how the cut percentages are around 50%. This implies that approximately half of the gene copies present in each DNA sample have been cut by the fusion proteins expressed by TALEN-F1 and TALEN-F2. Since all cells contain two copies of each gene, the result can be interpreted as at least one copy of the gene has been modified in almost all of the selected cells. In section 2 it is observed that the second transfection cycle produces an increase in the cut percentages. The Surveyor® method does not have sufficient precision to quantitatively establish the percentage of homozygous cuts, but in figure 7 it can be seen how the band corresponding to the wild alleles of 346 bp in CCR5 and 360 bp in CFTR has disappeared, giving way to other bands of different sizes. It can be concluded, therefore, that the method is effective for obtaining homozygous mutant cells.
    Example 4: Identification and enrichment of T lymphocytes subjected to the method of genetic modification according to the invention.
    5 To test the efficiency of the method in the production of T lymphocytes with two null copies of the CCR5 gene, an experiment was carried out in which the T-lymphocytes of heterozygous donors were used for the 32 mutation. T lymphocytes were nucleofected, according to the method of the invention, with a pair of specific bicistronic genes for the gene
    10 CCR5, each bicistronic gene encoding a fusion protein 100 comprising SEQ ID NO: 1 and a fluorescent protein 50. The fusion proteins obtained from the transcription of the two types of bicistronic gene are complementary having a specific binding domain for SEQ ID NO: 2 and the other a specific binding domain for SEQ ID NO: 3. One of the genes encodes an mCherry fluorescent protein and the other
    15 gene the EGFP protein. To determine the nuclease or shear activity of the fusion proteins of the invention, and at the same time determine the frequency of the wild allele of the CCR5 gene in the treated cell population, the Surveyor® method cited above was used. DNA samples were compared from the original untreated population, from the population immediately after nucleofection, but without being selected, and from the
    20 population obtained once the lymphocytes expressing the two fluorescent proteins were selected in the cell separator. Figure 8 shows the results obtained. It can be seen how the frequency of the wild allele decreases with treatment, until it practically disappears in the cell population selected by fluorescence.
    权利要求:
    Claims (20)
    [1]
    1. Nucleic acid molecule encoding a fusion protein, the nucleic acid molecule comprising 5´ --- 3´ transcription at least:
    (to) a nucleic acid sequence encoding a DNA binding domain, and
    (b) a nucleic acid sequence encoding a catalytic domain of the FokI type, where at its 3'-end it comprises a nucleic acid sequence encoding a peptide comprising between 18 and 23 amino acids.
    [2]
    2. Nucleic acid molecule according to claim 1, wherein the peptide is a peptide of type 2A.
    [3]
    3. Nucleic acid molecule according to claim 2, wherein the DNA binding domain is of the TALE type.
    [4]
    Four. Nucleic acid molecule according to claim 3, wherein in the 5'--- 3 'sense of transcription:
    (to) The nucleic acid sequence encoding the DNA binding domain comprises a first segment of between 150 and 600 base pairs, preferably between 470 and 550 base pairs, which encode the N-terminal end of a TALE protein and a signal from nuclear localization, a second segment of between 1100 and 2900 base pairs that encode the binding domain of the TALE type to DNA, and a third segment of between 40 and 850 base pairs that encode the Cterminal end of the TALE protein, and
    (b) the nucleic acid sequence encoding the catalytic domain of the FokI type comprises a first segment of between 550 and 600 base pairs, preferably between 590 and 600 base pairs, which encode the catalytic domain of the FokI type followed by a segment between 50 and 70 base pairs, preferably 69 base pairs, encoding the peptide comprising between 18 and 23 amino acids, preferably 21 amino acids.
    [5]
    5. Nucleic acid molecule according to claim 4, wherein the peptide is of the T2A type and comprises a sequence SEQ ID NO: 1.
    [6]
    6. Nucleic acid molecule according to any of the preceding claims, wherein in the 5'--- 3 'sense of transcription following the nucleic acid sequence encoding the peptide comprising between 18 and 23 amino acids,
    5 comprises a nucleic acid sequence encoding a transcription identifier protein.
    [7]
    7. Nucleic acid molecule according to claim 6, wherein the nucleic acid sequence encoding the transcription identifier protein comprises between
    10 700 and 1000 base pairs, and the transcription identifier protein is a fluorescent protein.
    [8]
    8. Nucleic acid molecule according to any of the preceding claims, in
    where the nucleic acid is a deoxyribonucleic acid molecule or a ribonucleic acid molecule.
    [9]
    9. Nucleic acid molecule according to any of the preceding claims, wherein said molecule forms a monocistronic gene or a polycistronic gene.
    10. Fusion protein comprising in the N-terminal to C-terminal sense at least one DNA binding domain and at least one FokI type catalytic domain, wherein said FokI type catalytic domain has its C-terminus attached terminal a peptide comprising between 18 and 23 amino acids.
    11. Fusion protein according to claim 10, wherein the DNA binding domain is of the TALE type.
    [12]
    12. Fusion protein according to claim 10 or 11, wherein the peptide is a peptide
    2A, preferably a peptide of type T2A. 30
    [13]
    13. Fusion protein according to any of claims 10 to 12, wherein the peptide comprises a sequence SEQ ID NO: 1.
    [14]
    14. Method for modifying the genetic material of a cell, which comprises the steps of:
    (i) provide a cell that contains a DNA target nucleotide sequence, and
    (ii) introducing into said cell at least one nucleic acid molecule according to any one of claims 1 to 9, or at least one nucleic acid molecule encoding at least one fusion protein according to any one of claims 10 to 13, and inducing the expression of said at least one nucleic acid molecule, or
    (iii) introducing into said cell at least one fusion protein according to any
    of claims 10 to 13, such that the binding domain recognizes the target nucleotide sequence and the catalytic domain of the FokI type can be cut into a nucleotide sequence adjacent to the target nucleotide sequence.
    [15]
    fifteen. Method according to claim 14, wherein at least one nucleic acid molecule according to claim 6 or 7 is introduced, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding a fluorescent protein.
    [16]
    16. Method according to claim 14, wherein at least two nucleic acid molecules according to claim 6 or 7 are introduced, wherein each nucleic acid molecule comprises a nucleic acid sequence encoding a fluorescent protein each fluorescent protein having an emission spectrum different.
    [17]
    17. Method according to claim 15 or 16, wherein the cells to which the genetic material has been modified are identified and selected based on the fluorescence emitted by said cells.
    [18]
    18. Method according to claim 17, wherein the selected cells are amplified in culture and the nucleic acid molecule or nucleic acid molecules are reintroduced, and wherein the cells to which the genetic material has been modified again. they are identified and selected based on the fluorescence emitted by said cells.
    [19]
    19. Method according to any of claims 14 to 18, wherein the genetic material is introduced into said cell by a viral vector system and / or by a non-viral vector system.
    Method according to any of claims 14 to 19, wherein the target nucleotide sequence is in the human CCR5 gene, which encodes a membrane correceptor present in T lymphocytes of the human immunodeficiency virus (HIV).
    [21]
    21. Method according to claim 20, wherein the modification of the genetic material of the T lymphocyte results in the removal and / or inactivation of the membrane correceptor.
    [22]
    22. Therapeutic composition comprising at least one nucleic acid molecule according to any one of claims 1 to 9, at least one fusion protein according to any one of claims 10 to 13 or at least one modified cell
    15 genetically according to any of claims 14 to 21.
    [23]
    23. Therapeutic composition according to claim 22 for the treatment of hereditary diseases.
    24. Therapeutic composition according to claim 22 for use in the treatment of AIDS.
    Fig. 1
    Fig. 2 Fig. 3
    Fig. 4 Fig. 5
    Fig. 6 Fig. 7
    Fig. 8

    <110> UNIVERSITY OF THE BASQUE COUNTRY / EUSKAL HERRIKO UNIBERTSITATEAUNIVERSITY OF BARCELONA FUNDACIÓ D'INVESTIGACIÓ SANITÀRIA DE LES ILLES BALEARS SUPERIOR COUNCIL OF SCIENTIFIC INVESTIGATIONS BIOPRAXIS RESEARCH AIE
    <120> Nucleic acid molecule, fusion protein and method to modify thegenetic material of a cell
    <130> BIO003
    <160> 3
    <170> BiSSAP 1.3
    <210> 1
    <211> 21
    <212> PRT
    <213> Nudaurelia capensis beta virus
    <400> 1Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu1 5 10 15Glu Asn Pro Gly Pro
    twenty
    <210> 2
    <211> 18
    <212> DNA
    <213> Homo sapiens
    <400> 2ttcattacac ctgcagct 18
    <210> 3
    <211> 17
    <212> DNA
    <213> Homo sapiens
    <400> 3cttccagaat tgatact 17
     one
    类似技术:
    公开号 | 公开日 | 专利标题
    Hackett et al.2005|Sleeping Beauty transposon‐mediated gene therapy for prolonged expression
    US20210139872A1|2021-05-13|Crispr having or associated with destabilization domains
    Hudecek et al.2017|Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
    CN105899665B|2019-10-22|The delivering method and composition being transformed for nuclease-mediated genome project
    Izsvák et al.2004|Sleeping beauty transposition: biology and applications for molecular therapy
    ES2895069T3|2022-02-17|Nuclease-mediated regulation of gene expression
    JP2019503716A|2019-02-14|Crystal structure of CRISPRCPF1
    US20200340012A1|2020-10-29|Crispr-cas genome engineering via a modular aav delivery system
    JP2017503485A|2017-02-02|CRISPR-CAS system and method for altering gene product expression, structural information, and inducible modular CAS enzyme
    ES2828663T3|2021-05-27|Nondisruptive Genetic Direction
    CN110114461A|2019-08-09|Novel C RISPR enzyme and system
    CN107249645A|2017-10-13|The method and composition of cell of interest is eliminated for selectivity
    WO2017136520A1|2017-08-10|Mitochondrial genome editing and regulation
    CA3076285A1|2019-03-28|Non-integrating dna vectors for the genetic modification of cells
    BR112020001364A2|2020-08-11|methods to test and modify the capacity of a crispr / cas nuclease.
    Ates et al.2020|Delivery approaches for therapeutic genome editing and challenges
    JP2018534114A5|2019-12-19|
    Cottle et al.2016|Treating hemoglobinopathies using gene-correction approaches: promises and challenges
    Ishikawa et al.2006|Phage ϕC31 integrase‐mediated genomic integration of the common cytokine receptor gamma chain in human T‐cell lines
    ES2594486B1|2017-09-26|Nucleic acid molecule, fusion protein and method to modify the genetic material of a cell
    Ewart et al.2019|A new era of genetic engineering for autoimmune and inflammatory diseases
    Sandoval-Villegas et al.2021|Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering
    US7919583B2|2011-04-05|Integration-site directed vector systems
    Antoniou et al.2021|Base and prime editing technologies for blood disorders
    Cecilia et al.2014|Codon swapping of zinc finger nucleases confers expression in primary cells and in vivo from a single lentiviral vector
    同族专利:
    公开号 | 公开日
    MA43246A|2018-09-26|
    ES2594486B1|2017-09-26|
    EP3312274A1|2018-04-25|
    WO2016203088A1|2016-12-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2011072246A2|2009-12-10|2011-06-16|Regents Of The University Of Minnesota|Tal effector-mediated dna modification|
    WO2012015938A2|2010-07-27|2012-02-02|The Johns Hopkins University|Obligate heterodimer variants of foki cleavage domain|
    US20140087426A1|2012-09-24|2014-03-27|The Chinese University Of Hong Kong|Transcription activator-like effector nucleases |
    KR101953237B1|2010-05-17|2019-02-28|상가모 테라퓨틱스, 인코포레이티드|Novel dna-binding proteins and uses thereof|
    EP2834357B1|2012-04-04|2017-12-27|Life Technologies Corporation|Tal-effector assembly platform, customized services, kits and assays|CN109206520A|2017-07-07|2019-01-15|中国科学院动物研究所|For the drug induced fusion protein and its encoding gene of genome editor and application|
    法律状态:
    2017-09-26| FG2A| Definitive protection|Ref document number: 2594486 Country of ref document: ES Kind code of ref document: B1 Effective date: 20170926 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201530874A|ES2594486B1|2015-06-19|2015-06-19|Nucleic acid molecule, fusion protein and method to modify the genetic material of a cell|ES201530874A| ES2594486B1|2015-06-19|2015-06-19|Nucleic acid molecule, fusion protein and method to modify the genetic material of a cell|
    MA043246A| MA43246A|2015-06-19|2016-06-17|NUCLEIC ACID MOLECULE, FUSION PROTEIN AND METHOD FOR MODIFYING THE GENETIC MATERIAL OF A CELL|
    EP16741971.2A| EP3312274A1|2015-06-19|2016-06-17|Nucleic acid molecule, fusion protein and method for altering the genetic material of a cell|
    PCT/ES2016/070459| WO2016203088A1|2015-06-19|2016-06-17|Nucleic acid molecule, fusion protein and method for altering the genetic material of a cell|
    [返回顶部]